argenx NV ADR (ARGX)vsEvommune, Inc. (EVMN)
ARGX
argenx NV ADR
$830.79
-2.70%
HEALTHCARE · Cap: $54.24B
EVMN
Evommune, Inc.
$11.59
+3.02%
HEALTHCARE · Cap: $409.17M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 53055% more annual revenue ($5.32B vs $10.00M). ARGX leads profitability with a 32.3% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
EVMN
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$2427.69
Current Price
$830.79
$1596.90 discount
Intrinsic value data unavailable for EVMN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 32.0%
Revenue surging 59.3% year-over-year
Earnings expanding 95.2% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 175.6x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 32.3% and operating margin at 32.0%. Revenue growth of 59.3% demonstrates continued momentum.
Bull Case : EVMN
The strongest argument for EVMN centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : EVMN
The primary concerns for EVMN are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ARGX profiles as a growth stock while EVMN is a value play — different risk/reward profiles.
ARGX is growing revenue faster at 59.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 30/100), backed by strong 32.3% margins and 59.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Evommune, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in this critical sector. With a promising pipeline and advanced research methodologies, Evommune is positioned to enhance immune response and improve patient outcomes. The company aims to establish a leading presence in the evolving immunotherapy market through its commitment to robust scientific practices and strategic partnerships. As it progresses through clinical trials, Evommune is striving to deliver transformative solutions that could redefine the standards of care in immunology, thereby significantly impacting patient quality of life.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?